Knockout of TLR4 or treatment with TNF-α antagonist or TLR4 blockers mitigates neuroinflammation, dopaminergic neuronal loss, and motor dysfunction in both cellular and rodent models of PD [66, 76, 78, 79]. The gene discussed is TNF; the disease is Parkinson disease.